CYTH Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc. is a biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is in three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (Clinical NCT02939547, NCT02912793 and NCT03893071) and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

As of 11/26/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/18/2011
Outstanding shares:  6,455,225
Average volume:  270,892
Market cap:   $34,212,693
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    23254X201
ISIN:        US23254X2018
Valuation   (See tab for details)
PE ratio:   -2.40
PB ratio:   4.47
PS ratio:   29.85
Return on equity:   -185.84%
Net income %:   -1,236.57%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy